466 related articles for article (PubMed ID: 29127675)
1. Clinical Features of β-Thalassemia and Sickle Cell Disease.
McGann PT; Nero AC; Ware RE
Adv Exp Med Biol; 2017; 1013():1-26. PubMed ID: 29127675
[TBL] [Abstract][Full Text] [Related]
2. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
Cui S; Engel JD
Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681
[TBL] [Abstract][Full Text] [Related]
4. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
5. [Study of hemoglobinopathies found in Belgium].
Fondu P
Bull Mem Acad R Med Belg; 1995; 150(10-11):367-75; discussion 376-8. PubMed ID: 8845787
[TBL] [Abstract][Full Text] [Related]
6. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
7. Advances in the Treatment of Sickle Cell Disease.
Kapoor S; Little JA; Pecker LH
Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
[TBL] [Abstract][Full Text] [Related]
8. Treatment Options for Sickle Cell Disease.
Meier ER
Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic reactivation of fetal haemoglobin.
Olivieri NF; Weatherall DJ
Hum Mol Genet; 1998; 7(10):1655-8. PubMed ID: 9735388
[TBL] [Abstract][Full Text] [Related]
10. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia.
Flanagan JM; Steward S; Hankins JS; Howard TM; Neale G; Ware RE
Am J Hematol; 2009 Jun; 84(6):328-34. PubMed ID: 19384939
[TBL] [Abstract][Full Text] [Related]
11. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
12. Sickle cell disease: current treatment and emerging therapies.
Neumayr LD; Hoppe CC; Brown C
Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007
[TBL] [Abstract][Full Text] [Related]
13. Treatment of sickling disorders.
Charache S
Curr Opin Hematol; 1996 Mar; 3(2):139-44. PubMed ID: 9372064
[TBL] [Abstract][Full Text] [Related]
14. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
15. Study of alpha hemoglobin stabilizing protein expression in patients with β thalassemia and sickle cell anemia and its impact on clinical severity.
Mahmoud HM; Shoeib AA; Abd El Ghany SM; Reda MM; Ragab IA
Blood Cells Mol Dis; 2015 Dec; 55(4):358-62. PubMed ID: 26460260
[TBL] [Abstract][Full Text] [Related]
16. Management of Sickle Cell Disease in Children.
Noronha SA; Sadreameli SC; Strouse JJ
South Med J; 2016 Sep; 109(9):495-502. PubMed ID: 27598348
[TBL] [Abstract][Full Text] [Related]
17. Sickle Cell Disease: A Brief Update.
Azar S; Wong TE
Med Clin North Am; 2017 Mar; 101(2):375-393. PubMed ID: 28189177
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
[TBL] [Abstract][Full Text] [Related]
19. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians.
Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A
Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131
[TBL] [Abstract][Full Text] [Related]
20. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases.
Italia KY; Jijina FF; Chandrakala S; Nadkarni AH; Sawant P; Ghosh K; Colah RB
J Clin Pharmacol; 2010 Feb; 50(2):231-4. PubMed ID: 19797538
[No Abstract] [Full Text] [Related]
[Next] [New Search]
